# A Study to Evaluate the Efficacy and the Change of sAg Levels in Chronic Hepatitis B Patients Receiving Clevudine Treatment Over the Long Period

> **NCT01264094** · PHASE4 · TERMINATED · sponsor: **Bukwang Pharmaceutical** · enrollment: 200 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Clevudine

## Key facts

- **NCT ID:** NCT01264094
- **Lead sponsor:** Bukwang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2014-11
- **Final completion:** 2015-06
- **Target enrollment:** 200 (ESTIMATED)
- **Why stopped:** Enrollment
- **Last updated:** 2015-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01264094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01264094, "A Study to Evaluate the Efficacy and the Change of sAg Levels in Chronic Hepatitis B Patients Receiving Clevudine Treatment Over the Long Period". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01264094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*